caa a22 4500 445338261 CHVBK 20180317142803.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1245/s10434-010-1321-8 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1321-8 Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study [Elektronische Daten] [Jun Luo, Rong-Ping Guo, Eric Lai, Yao-Jun Zhang, Wan Lau, Min-Shan Chen, Ming Shi] Background: For patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) compared with conservative treatment largely remains controversial. The objective of this study was to determine whether TACE confers a survival benefit to patients with HCC and PVTT, and to uncover prognostic factors. Methods: Between July 2007 and July 2009, a prospective two-arm nonrandomized study was performed on consecutive patients with unresectable HCC with PVTT. In one arm, patients were treated by TACE using an emulsion of lipiodol and anticancer agents ± gelatin sponge embolization. In another arm, patients received conservative treatment. Results: A total of 164 patients were recruited for the study (TACE group, n = 84; conservative treatment group, n = 80). Patients in the TACE group received a mean of 1.9 (range, 1-5) TACE sessions. The overall median survival for all patients was 5.2months, and the 12- and 24-month overall survival rates were 18.3% and 5.6%, respectively. The 12- and 24-month overall survival rates for the TACE and conservative groups were 30.9%, 9.2%, and 3.8%, 0%, respectively. The TACE group had significantly better survivals than the conservative group (P < 0.001). On subgroup analysis of segmental and major PVTT, the TACE group also had significantly better survivals (P = 0.002, P = 0.002). The treatment type, PVTT extent, tumor size, and serum bilirubin were independent prognostic factors of survival on multivariate analysis. Conclusions: TACE was safe and feasible in selected HCC patients with PVTT and it had survival benefit over conservative treatment. Society of Surgical Oncology, 2010 Luo Jun Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut Guo Rong-Ping Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut Lai Eric Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China aut Zhang Yao-Jun Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut Lau Wan Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China aut Chen Min-Shan Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut Shi Ming Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 413-420 1068-9265 18:2<413 2011 18 10434 https://doi.org/10.1245/s10434-010-1321-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1321-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Luo Jun Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Guo Rong-Ping Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Lai Eric Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China aut NATIONALLICENCE 700 1- Zhang Yao-Jun Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Lau Wan Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China aut NATIONALLICENCE 700 1- Chen Min-Shan Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Shi Ming Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 413-420 1068-9265 18:2<413 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer